QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:PGEN

Precigen Stock Forecast, Price & News

$4.50
-0.08 (-1.75 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.42
$4.64
50-Day Range
$4.60
$6.26
52-Week Range
$3.95
$11.10
Volume
978,168 shs
Average Volume
1.32 million shs
Market Capitalization
$929.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
30 days | 90 days | 365 days | Advanced Chart
Receive PGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.


Precigen logo

About Precigen

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGEN
Employees
194
Year Founded
N/A

Sales & Book Value

Annual Sales
$103.18 million
Book Value
$0.36 per share

Profitability

Net Income
$-170.52 million
Net Margins
-107.46%
Pretax Margin
-108.15%

Debt

Price-To-Earnings

Miscellaneous

Free Float
118,406,000
Market Cap
$929.89 million
Next Earnings Date
11/8/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Optionable

MarketRank

Overall MarketRank

2.44 out of 5 stars

Medical Sector

161st out of 1,372 stocks

Pharmaceutical Preparations Industry

66th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Precigen (NASDAQ:PGEN) Frequently Asked Questions

Is Precigen a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Precigen stock.
View analyst ratings for Precigen
or view top-rated stocks.

What stocks does MarketBeat like better than Precigen?

Wall Street analysts have given Precigen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precigen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Precigen's next earnings date?

Precigen is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Precigen
.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Monday, August, 9th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biotechnology company had revenue of $33.58 million for the quarter, compared to analysts' expectations of $22.48 million. Precigen had a negative trailing twelve-month return on equity of 70.74% and a negative net margin of 107.46%.
View Precigen's earnings history
.

How has Precigen's stock price been impacted by COVID-19 (Coronavirus)?

Precigen's stock was trading at $2.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PGEN stock has increased by 89.1% and is now trading at $4.50.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PGEN?

5 analysts have issued 12-month target prices for Precigen's shares. Their forecasts range from $10.00 to $14.00. On average, they expect Precigen's share price to reach $12.80 in the next twelve months. This suggests a possible upside of 184.4% from the stock's current price.
View analysts' price targets for Precigen
or view top-rated stocks among Wall Street analysts.

Who are Precigen's key executives?

Precigen's management team includes the following people:
  • Helen Sabzevari, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Rutul R. Shah, Head-Operations & Portfolio
  • Harry Thomasian, Chief Financial Officer
  • Thomas David Reed, Chief Science Officer
  • Douglas E. Brough, Head-Research

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), The Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

What is Precigen's stock symbol?

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Who are Precigen's major shareholders?

Precigen's stock is owned by many different institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.42%), Chiron Capital Management LLC (0.04%), Sanders Morris Harris LLC (0.02%) and Gateway Advisory LLC (0.01%). Company insiders that own Precigen stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Thomas Bostick and Trading SA Ares.
View institutional ownership trends for Precigen
.

Which major investors are buying Precigen stock?

PGEN stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Gateway Advisory LLC, Sanders Morris Harris LLC, and Chiron Capital Management LLC. Company insiders that have bought Precigen stock in the last two years include Randal J Kirk, and Trading SA Ares.
View insider buying and selling activity for Precigen
or or view top insider-buying stocks.

How do I buy shares of Precigen?

Shares of PGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precigen's stock price today?

One share of PGEN stock can currently be purchased for approximately $4.50.

How much money does Precigen make?

Precigen has a market capitalization of $929.89 million and generates $103.18 million in revenue each year. The biotechnology company earns $-170.52 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Precigen have?

Precigen employs 194 workers across the globe.

What is Precigen's official website?

The official website for Precigen is www.precigen.com.

Where are Precigen's headquarters?

How can I contact Precigen?

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at (301) 556-9900 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.